Skip to main content

Advertisement

Table 3 Adjusted primary and secondary outcomes over the 12-week treatment period

From: Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study

   Significance for between group differences at follow-ups *
Outcome 0-6 wks 0-12 wks
Primary WOMAC   
  Pain 0.43 0.08
  Stiffness 0.23 0.08
  Function 0.85 0.04*
  Total 0.60 0.03*
  ALF 0.31 0.09
  SF-36 0.98 0.54
  VAS 0.06 0.05*
Secondary KSKS 0.43 0.09
  KSFS 0.29 0.63
  1. * The significance threshold was set at p ≤ 0.05.
  2. WOMAC = Western Ontario and McMaster Osteoarthritis Index; ALF = Aggregated locomotor function; SF-36 = 36-item short-form health survey; VAS = Visual-analogue-scale for pain; KSKS = Knee society knee score; KSFS = Knee society function score.